Stray Dog

Palantir CTO sells $64.9 million of shares; NHS pilots unused

  • Bad news: Chief technology officer Sankar sold about $64.9 million of shares over two days under a pre-set 10b5-1 plan, after the 85% rise in equity awards.
  • Bad news: The two flagship NHS Cancer 360 success cases had zero logged-in users over 12 months, so low take-up of one product is a real weakness.
Read the full notes

Two negative signals have landed together at Palantir. First, chief technology officer Sankar sold 384,680 shares over two days, about $64.9 million, under a pre-set 10b5-1 plan. Set against the 85% rise in equity awards on 2 Nov, the pattern of receiving shares and then selling them is worth tracking.

Read more

Second, the NHS Cancer 360 pilot, four years in, is officially used by only 5 to 6 trusts, and in Freedom of Information replies the two flagship success cases had zero logged-in users over the past 12 months. The weakness of the Federal Data Platform is low penetration of a single product, not just political resistance.

Key evidence

  • Form 4 filed on 13 Nov (checked against the original on EDGAR): on 10 Nov Sankar converted 300,000 Class B shares to Class A and sold them on the open market (C to S), about $50.1 million; on 11 Nov he did the same with 84,680 shares, about $14.8 million
  • Total over the two days: 384,680 shares, about $64.9 million; the 10b5-1 plan was set up on 10 Aug (nearly three months before earnings)
  • After the sales he directly holds about 858,000 Class A shares (Class B and trust holdings not included)
  • Classified as S (voluntary sale), not F (tax withholding), but executed under a pre-set plan
  • An earlier Form 144 gave the source as RSUs, but what was actually sold was converted Class B stock (which carries super-voting rights and dilutes the founding team's voting control, though 380,000 shares is a very small amount)
  • On 28 Oct Sankar had just been granted 565,000 shares (code A); this sale is about 68% of that grant
Show 6 more
  • NHS Cancer 360 pilot, four years in: the official figure in Mar 2026 was 5 trusts using it (2 listed as benefiting); data in October said 6 (5 benefiting) and was later taken off the web page
  • The two officially promoted success pilots (Chelsea and Westminster, Royal United Hospitals Bath) had zero logged-in users over the past 12 months, according to FOI replies
  • East Lancashire is on the list of users but has only 1 user, and itself confirmed it has not gone live on the Federal Data Platform
  • East Kent (no immediate need) and Bedfordshire (metadata requirements problem) declined of their own accord
  • On 13 Nov the NHS took down its list of 137 beneficiaries, so the claimed results of the flagship use cases do not hold up
  • Source: The Register, 13 Nov, citing official NHS England data and FOI replies

Catalysts to watch

  • Follow-up insider Form 4 filings: whether receiving and then selling shares becomes a regular rhythm
  • Risk of replacement before the NHS Federal Data Platform contract expires in 2029
  • Whether the NHS adjusts its Cancer 360 claims further
  • The next equity award approval (the 85% rise on 2 Nov is the baseline)

Risks

  • The first large voluntary sale by a chief-technology-officer-level insider after earnings, on top of the 85% rise in equity awards on 2 Nov, makes the insider cycle worth tracking
  • The NHS flagship healthcare platform's showcase narrative is damaged (a reputational cost for sales elsewhere)
  • Low penetration of a single product on the Federal Data Platform is a hard weakness, not just political resistance
  • The long-term risk of being replaced in 2029

Sources 4

  1. SEC EDGAR Form 4, 13 Nov (Sankar)
  2. The Register report, 13 Nov
  3. Official NHS England data and Freedom of Information (FOI) replies
  4. Comparison of Form 144 disclosure with actual trades on Form 4